EUVIMEDEUVIMED entdecken
Open Access

Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease

Iyas Daghlas iD, Dipender Gill iD

Journal of the American Heart Association · 16.12.2025 · 14 (24)

DOI: 10.1161/jaha.125.043972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 16.12.2025. Verfasst von Iyas Daghlas und 1 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA. Hauptthemen laut MEDLINE: Interleukin-6, Blood Coagulation, Venous Thromboembolism, Receptors, Interleukin-6. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although genetic evidence supports IL‐6 (interleukin‐6) signaling inhibition as protective against atherosclerotic disease, its potential effects on thromboembolic outcomes are not well established. We conducted a Mendelian randomization analysis to investigate the association of genetically proxied IL‐6 signaling inhibition with venous thromboembolism, cardioembolic stroke, and coagulation cascade protein levels.

Methods

IL‐6 signaling inhibition was proxied using the rs2228145 IL6R missense variant, which impairs classical IL‐6 signaling and lowers CRP (C‐reactive protein) levels. Genetic associations with thromboembolic disease outcomes were obtained from genome‐wide association studies of venous thromboembolism (81 190 cases) and cardioembolic stroke (10 804 cases). As atherosclerotic comparator traits, we included coronary artery disease (181 522 cases) and large‐artery atherosclerotic stroke (6399 cases). Genetic associations with 35 coagulation cascade protein levels were obtained from the UK Biobank (n=6218) and deCODE cohorts (n=35 559). Mendelian randomization estimates were derived using the Wald ratio method, scaled per 1‐unit decrease in natural log‐transformed CRP levels.

Results

Genetically proxied IL‐6 signaling inhibition was associated with increased risk of venous thromboembolism (odds ratio [OR], 1.31 [95% CI, 1.16–1.47], P =6.5×10 −6 ) but not with cardioembolic stroke (OR, 1.25 [95% CI, 0.73–2.14], P =0.42). Conversely, protective associations were observed for both coronary artery disease and large‐artery atherosclerotic stroke. Proteomic analyses demonstrated significant reductions in levels of 5 procoagulant and 7 anticoagulant or antifibrinolytic proteins.

Conclusions

These findings suggest that IL‐6 signaling inhibition dysregulates coagulation homeostasis and increases venous thromboembolism risk. Further experimental, translational, and epidemiologic studies are warranted to delineate underlying mechanisms and to evaluate thromboembolic safety in pharmacologic IL‐6 signaling inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Blood CoagulationVenous ThromboembolismReceptors, Interleukin-6Embolic StrokeHumansMendelian Randomization AnalysisSignal TransductionRisk FactorsGenome-Wide Association StudyDown-RegulationMaleC-Reactive ProteinFemaleRisk AssessmentGenetic Predisposition to DiseasePolymorphism, Single NucleotideMiddle Aged

Stichwörter der Autor:innen

cardioembolic strokecoagulationinterleukin‐6proteomicsvenous thromboembolism

Substanzen

Interleukin-6IL6 protein, humanC-Reactive ProteinReceptors, Interleukin-6IL6R protein, human

Autor:innen und Institutionen

  • UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA.
  • Department of Epidemiology and Biostatistics School of Public Health, Imperial College London London United Kingdom.

ORCID-Profile: Iyas Daghlas, Dipender Gill

Zitieren

APA

Daghlas, I., & Gill, D. (2025). Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease. Journal of the American Heart Association, 14(24). https://doi.org/10.1161/jaha.125.043972

Vancouver

Daghlas I, Gill D. Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease. Journal of the American Heart Association. 2025;14(24). doi:10.1161/jaha.125.043972

BibTeX
@article{Daghlas2025,
  author = {Daghlas, Iyas and Gill, Dipender},
  title = {Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {24},
  doi = {10.1161/jaha.125.043972}
}
Kostenlos starten →